Alume Biosciences Secures $13 Million in Series B Financing Round

Alume intends to put the raised funds toward advancing the company’s lead candidate ALM-488, a peptide-dye conjugate designed to highlight nerves with fluorescence in real- time during surgery. Alume announced in August 2022 that the first patient had been dosed in a Phase 3 pivotal study of ALM-488 for intra-operative visualization of nerves in head and neck surgery.

The San Diego-based Pillsbury deal team included Corporate partner Mike Hird, Corporate associate Alexander Graham and Senior Legal Analyst Rory O’Neill.

Click here to read the full company press release.